Korea Research Institute of Bioscience and Biotechnology

Lg Chem, Ltd

Jeong-Min Kim

In-Sung Song

Nam-Soon Kim

Cheol-Hee Kim

Hyun-Taek Kim

So-Young Jeong

Yong-Ho Lee

Ki-Soo Lee

Min-Seok Cho

Heon-Yong Kwon

Dae-Sik Hong

Seon-Kyoung Kim

Kyoung-Chan Lim

Man-Seong Jeon

Jin-Man Kim

Joo Heon Kim

Yeo-Jin Jeon

Ga Hee Ha

Soo Young Jun

Nang-Su Oh

Ga-Hee Ha

The present description relates to an olefin block copolymer with enhanced processability as well as excellences in elasticity and heat resistance, and a preparation method for the same. The olefin block copolymer includes first and second segments, each containing an ethylene or propylene repeating unit and an &#x3b1;-olefin repeating unit at different mole fractions, where the second segment is dispersed in the form of a closed curve as a dispersed phase on the first segment according to a TEM (Transmission Electron Microscope) image.

Olefin block copolymer

The present invention relates to a pharmaceutical composition, including inhibitors for expression or activity of TIP41 protein, for prevention and treatment of cancer. When the liver cancer cell lines, showing resistance to TRAIL, are treated with TIP41 siRNA and TRAIL, apoptosis is induced in cancer cell. The same effect is found in cases of lung cancer and colon cancer with resistance against TRAIL. Moreover, this induction of apoptosis by TIP41 siRNA and TRAIL was confirmed in tumor xenograft, which was injected with Huh7 liver cancer cells and then was subjected to TIP41 siRNA transfection and TRAIL treatment. In addition, it was confirmed through animal experiments in which the tumor size has reduced and apoptosis was induced by treatment with TIP41 siRNA and TRAIL. Of note, MKK7/JNK pathway was confirmed to mediate the apoptosis induced by the application of TIP41 siRNA and TRAIL. The apoptosis were verified to be caused by the activation of MKK7/JNK signaling pathway. Taken together, the present invention provide the strong evidence that the pharmaceutical composition, including inhibitors for TIP41 expression or activity can be used for cancer prevention and treatment as well as an anti-cancer adjuvant. Taken together, the pharmaceutical composition comprising inhibitors for expression or activity of TIP41 protein may be used for prevention and treatment of cancer or as an anti-cancer adjuvant.

Composition for enhancing TRAIL sensitivity comprising inhibitors for expression or activity of TIP41 as a target gene of TRAIL sensitizer

The present invention relates to a diagnostic marker containing ZNF312b gene and the fragment thereof, a diagnostic method for stomach cancer and a screening method for stomach cancer inducers or inhibitors using the same. ZNF312b gene expression is specifically increased in stomach cancer. And the over-expression or the under-expression of the gene affects activation or inhibition of cell proliferation and tumor formation of a stomach cancer cell line and cell proliferation signal transduction system as well to induce stomach cancer at last. Therefore, ZNF312b marker gene can be effectively used for diagnosis of stomach cancer, construction of a stomach cancer animal model, prevention and treatment of stomach cancer and development of a stomach cancer specific anticancer agent.

Gastric carcinoma gene ZNF312b, a protein translated from the gene, and a diagnostic kit and a screening method for anticancer agents using the same

Growing community of inventors

Daejeon, South Korea

Jeong-Min Kim